In ongoing treatments, the last data point refers to the time of the last documented administration of a degarelix dose. Change in PSA, S-ALP, and prostate volume are summarized using descriptive ...

A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on ...

A total of 1,010 patients received degarelix and were included. Baseline demographic and disease characteristics of the registry population are summarized in Table 2. Around two-thirds of patients ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

NICE has published final guidance recommending funding for Ferring’s Firmagon (degarelix) treatment for hormone-dependent prostate cancer. The decision followed a successful appeal by Ferring ...